1. Home
  2. CALC vs FAAS Comparison

CALC vs FAAS Comparison

Compare CALC & FAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • FAAS
  • Stock Information
  • Founded
  • CALC 2011
  • FAAS 2021
  • Country
  • CALC United States
  • FAAS Indonesia
  • Employees
  • CALC N/A
  • FAAS N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • FAAS
  • Sector
  • CALC Health Care
  • FAAS
  • Exchange
  • CALC Nasdaq
  • FAAS NYSE
  • Market Cap
  • CALC 36.0M
  • FAAS 29.1M
  • IPO Year
  • CALC N/A
  • FAAS N/A
  • Fundamental
  • Price
  • CALC $2.71
  • FAAS $0.52
  • Analyst Decision
  • CALC Strong Buy
  • FAAS
  • Analyst Count
  • CALC 5
  • FAAS 0
  • Target Price
  • CALC $18.20
  • FAAS N/A
  • AVG Volume (30 Days)
  • CALC 30.8K
  • FAAS 433.0K
  • Earning Date
  • CALC 03-27-2025
  • FAAS 09-17-2024
  • Dividend Yield
  • CALC N/A
  • FAAS N/A
  • EPS Growth
  • CALC N/A
  • FAAS N/A
  • EPS
  • CALC N/A
  • FAAS N/A
  • Revenue
  • CALC N/A
  • FAAS $57,730,593.00
  • Revenue This Year
  • CALC N/A
  • FAAS N/A
  • Revenue Next Year
  • CALC N/A
  • FAAS N/A
  • P/E Ratio
  • CALC N/A
  • FAAS N/A
  • Revenue Growth
  • CALC N/A
  • FAAS 38.16
  • 52 Week Low
  • CALC $2.05
  • FAAS $0.38
  • 52 Week High
  • CALC $6.27
  • FAAS $13.64
  • Technical
  • Relative Strength Index (RSI)
  • CALC 43.94
  • FAAS 42.49
  • Support Level
  • CALC $2.32
  • FAAS $0.43
  • Resistance Level
  • CALC $3.05
  • FAAS $0.55
  • Average True Range (ATR)
  • CALC 0.27
  • FAAS 0.11
  • MACD
  • CALC -0.01
  • FAAS -0.01
  • Stochastic Oscillator
  • CALC 43.29
  • FAAS 22.35

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.

About FAAS DIGIASIA CORP

DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.

Share on Social Networks: